Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01415752
Title Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Eastern Cooperative Oncology Group
Indications

mantle cell lymphoma

Therapies

Bortezomib

Bendamustine

Rituximab

Lenalidomide

Age Groups: senior | adult
Covered Countries USA | CAN


No variant requirements are available.